Evaluation of the Vaccine Effectiveness in the Field of Rotarix® in Children Aged 0 to 2 Years in Certain District Hospitals of the Center Region-Cameroon
Main Article Content
Abstract
Summary
Rotavirus (RV) is the main cause of acute gastroenteritis (GE) in children under 5 years of age with a high incidence between the ages of 6 and 23 months. After one year of introduction in the EPV in Cameroon, it was interesting to evaluate the vaccine efficacy of Rotarix in the field. To this end, we set ourselves the objective of evaluating the field efficacy of Rotarix® in children aged 2 to 24 months in selected District Hospitals of the Centre-Cameroon Region. We conducted a case-control study in children aged 2 to 24 months ; 77 subjects were included in our study and stool samples were collected from March to August of 2015. Antigenic detection of Rotavirus was carried out by an immunochromatographic test (rapid test). We had a sex ratio of 1.3 in favour of the male sex ; the age groups most represented were those of 2 to 6 months and 18-24 months, i.e. 28.6% each ; 50 subjects had been vaccinated (exposure to the protection factor) with 1 positive case and 27 non-vaccinated with 6 positive cases, i.e. a vaccination coverage of 64.94%. Of the subjects found positive, those in the 2-12 months age group represented 42.9%, compared to 57.1%. For vaccine efficacy, statistical analysis was performed using Epi info software version 7.1.3.0 and the odds ratio was estimated to be 0.0714 with 95% CI bounds 0.0081; 0.6305. The resulting field efficacy according to the WHO proposed formula is 92.86% with 95% bounds of CI 36.95% to 99.19%. These results should be complemented by similar studies for each region of the country to determine the field efficacy of Rotarix in Cameroon.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. GOFFARD A. 2012. Rotavirus infections. FACULTY OF PHARMACEUTICAL AND BIOLOGICAL SCIENCES OF LILLE., P 7.
II. VAES-TARAL F. 2002. Nosocomial rotavirus infections in children under 4 years old, hospitalized for bronchiolitis: review of the literature and results of a 3-month prospective study conducted during the winter of 1999-2000. Thesis N° 150 presented and defended publicly within the framework of the third cycle of Medicine at the UNIVERSITE HENRI POlNCARE, NANCY 1, FACULTY OF MEDICINE OF NANCY.
III. Lorrot M, Vasseur M, Bourrillon A. 2005. Pathophysiology of rotavirus diarrhea. review of Virology; 9(1): 9-18
IV. Salvadori M, Le Saux N. 2010. Recommendations for the use of rotavirus vaccines in infants. Paediatrics & Child Health 15(8): 524–528.
V. Bernstein D. 2009. Rotavirus overview. The Pediatric Infectious Disease Journal; 28(3): 50-53.
VI. Umesh D P, Anthony B, Claudio L, Cynthia B P, Kenji S, Duncan S, Maureen B, Roger I G. 2009; Global mortality associated with rotavirus disease among children in 2004. J Infect Di; 1;200 Suppl 1: S9-S15.
VII. A. Duncan S, Nigel C, John T, Shabir A, Beatrice De V, Alain B. 2009. A Review of Rotavirus Infection in and Vaccination of Human Immunodeficiency Virus–Infected Children. The Journal of Infectious Diseases, Volume 200, Pages S57–S62,
VIII. Karla S.W, Harriet M, Hanna B, Irit B, Sukrti N, Elad G, Fémi P, Nigel C. 2012. Vaccines for preventing rotavirus diarrhoea: vaccines in use
IX. WHO, 2012. Global Rotavirus Information and Surveillance Bulletin, 7, pages 11. http://www.who.int/immunization/diseases/rotavirus/RV_bulletin_Jan_June_2012_Fi nal.pdf accédé le 20 octobre 2015
X. Access to vaccines, 2014. Rotavirus infections and preventive vaccines in Cameroon. PATH; Pages 3. www.Path.org.
XI. Steele A, Neuzil K, Cunliffe N, Madhi S, Bos P, Ngwira B et al., 2012. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial, BMC Infectious Diseases. 12 :213 pages 8
XII. Buyse H, Vinals C, Karkada N, Han H. The human rotavirus vaccine Rotarix™ in infants an integrated analysis of safety and reactogenicity. Human Vaccines Immunotherapeutics , 2014; 10(1):19–24.
XIII. ETOA R. 2009. Clinical, epidemiological and virological aspects of rotavirus gastroenteritis in children under five years in Yaounde Cameroon. Thesis presented with a view to obtaining a Doctorate in Medicine at the University of Yaounde I, FACULTY OF MEDICINE AND BIOMEDICAL SCIENCES.
XIV. Fadoua T. 2010. Acute rotavirus gastroenteritis in infants (about 42 cases). Thesis N°076 /10 publicly presented and defended on 21/04/10 for obtaining the doctorate in medicine at the university sidi mohhamed ben abdellah, faculty of medicine and pharmacy.
XV. Akoua-Koffi C, Akran V, Peenze I, Adjogoua V, Beer M, Steele A, Dosso M, Ehouman A. Epidemiological and virological aspects of diarrhea due to Rotavirus in Abidjan, Ivory Coast (1997-2000). Virologie Bull Soc Pathol Exot, 2007; 100, 4, 246-249.
XVI. DETOL K. 2015. Evaluation of vaccination coverage against Rotavirus in the city of Yaounde. Thesis presented and defended with a view to obtaining a Doctorate in Medicine at the University of Yaoundé I, FACULTY OF MEDICINE AND BIOMEDICAL SCIENCES.
XVII. Vicente B, Rodrigo D , Rodolfo C , Olga T , Maria Mercedes C , Eduardo O.B , Romulo E.C. 2012. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. International Journal of Infectious Diseases. 16 (94–98).
XVIII. Braeckman T, Herck K, Meyer N, Pirçon J, Soriano-Gabarró M, Heylen E, Zeller M, Azou M, Capiau H, Koster J, Maernoudt A, Raes M, Verdonck L, Verghote M, Vergison A, Matthijnssens J, Ranst M, Van Damme P. 2012 . Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ; 345:4752:4752.
XIX. Shabir A, Nigel A, Duncan S, Desirée W, Mari K, Cheryl L, Bagrey N, John C, Paul H, Brigitte B, Htay H, Kathleen M. 2010. Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants; The NEW ENGLAND JOURNAL of MEDICINE; 362 (4): 289-298
XX. Bernstein D. 2007. RIX4414 (Rotarix™): a live attenuated human rotavirus vaccine. Journal de Pediatria ; 83(3) :193-195.
XXI. Cortese M, Immergluck L, Held M, Jain S, Chan T, Grizas A, Khizer S, Barrett C, Quaye O, Mijatovic-Rustempasic S, Gautam R, Bowen M, Moore J, Tate J, Parashar U, Vázquez M. Effectiveness of Monovalent and Pentavalent Rotavirus Vaccine; PEDIATRICS; 132 (1): 25-33.
XXII. Desai R, Oliveira H, Parashar U, Lopman B, Tate J, Patel M. 2011. Reduction in morbidity and mortality from childhood diarrhoeal disease after species A rotavirus vaccine introduction in Latin America – A Review. Mem Inst Oswaldo Cruz; 106(8):907-911.
XXIII. Palma O, Cruz L, Ramos H, Baires A, Villatoro N, Pastor D. 2010. Effectiveness of rotavirus vaccination against childhood diarrhea in El Salvador: case-control study, BMJ; 341:c2825. Pages 7, DOI:10.1136/bmj.c2825.
XXIV. Boom J, Tate J, Sahni L, Rench M, Hull J, Gentsch J, Patel M, Baker C, Parashar U. 2009. Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States. PEDIATRICS; 125(2):199-207.